Atlas Trials

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Clinical trial NCT02316197 · COMPLETED

Trial details

NCT number
NCT02316197
Sponsor
Merck KGaA, Darmstadt, Germany
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid TumorsChronic Lymphocytic Leukemia
Start date
2014-12-31
Primary completion
2017-06-29
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.